Compare ARTNA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | LCTX |
|---|---|---|
| Founded | 1905 | 1990 |
| Country | United States | United States |
| Employees | 274 | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 301.7M |
| IPO Year | N/A | 1996 |
| Metric | ARTNA | LCTX |
|---|---|---|
| Price | $33.37 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 26.0K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $7.82 | $109.40 |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $30.50 | $0.85 |
| 52 Week High | $34.90 | $2.09 |
| Indicator | ARTNA | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.71 | 51.14 |
| Support Level | $31.86 | N/A |
| Resistance Level | $33.79 | $1.32 |
| Average True Range (ATR) | 0.68 | 0.07 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 97.06 | 72.52 |
Artesian Resources Corp operates as a holding company based in the United States. Through its subsidiaries, it offers water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The Group distributes and sells water, including water for public and private fire protection, to residential, commercial, industrial, municipal, and utility customers. Additionally, it is involved in contract water and wastewater operations; offers wastewater services, and water, sewer, and internal Service Line Protection Plans. The Group operates its businesses mainly through one reportable segment, the Regulated Utility segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.